BioSpace News Archive

Theseus Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company’s lead candidate THE-630, a small-molecule oral pan-variant KIT inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST).

KalVista Pharmaceuticals, Inc. announced that new data on KVD900, KalVista’s lead drug program for oral on-demand treatment of hereditary angioedema attacks, will be presented at the American Academy of Allergy, Asthma & Immunology Annual Scientific Meeting 2022, taking place in Phoenix, AZ and virtually, from February 25-28, 2022.

Phase 2/3 trial data, the basis for submission, demonstrates Rylaze maintains a clinically meaningful level of nadir serum asparaginase activity throughout the entire duration of treatment for adult and pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma.

TRACON Pharmaceuticals today announced that the National Cancer Institute (NCI) has initiated a randomized Phase 2 trial of TRC102 in combination with chemoradiation in patients with stage III non-squamous non-small cell lung cancer.

AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2021.

VBL Therapeutics announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will participate in a fireside chat at the Guggenheim Oncology Conference being held virtually on February 9 – 11, 2022.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company will be participating in the Guggenheim Oncology Conference taking place virtually February 9, 2022, through February 11, 2022.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it commenced trading on the NASDAQ Capital Markets as of today, February 2, 2022.

Amedisys, Inc. announced today that it has signed a definitive agreement to acquire Evolution Health.

BioRestorative Therapies, Inc. today announced that the Japanese Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem ® Program.